Gadina et al., 1991 - Google Patents
Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma MAb MOv18Gadina et al., 1991
- Document ID
- 18434881074769268143
- Author
- Gadina M
- Canevari S
- Ripamonti M
- Mariani M
- Colnaghi M
- Publication year
- Publication venue
- International journal of radiation applications and instrumentation. Part B. Nuclear medicine and biology
External Links
Snippet
The in vivo behavior of the monoclonal antibody (MAb) MOv18, with a restricted specificity for human ovarian carcinoma was analyzed on normal and tumor-bearing animals. The pharmacokinetics of the iodine-labeled MAb carried out in BALB/c mice fits an open two …
- 230000036231 pharmacokinetics 0 title abstract description 11
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
- A61K51/1003—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Paganelli et al. | Intraperitoneal radio‐localization of tumors pre‐targeted by biotinylated monoclonal antibodies | |
| Larson et al. | Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. | |
| Goodwin et al. | Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens | |
| Paganelli et al. | Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin | |
| AU613318B2 (en) | Affinity enhancement system | |
| Kukis et al. | Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates | |
| US5990286A (en) | Antibodies with reduced net positive charge | |
| Casalini et al. | Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization | |
| Stoldt et al. | Pretargeting strategies for radio-immunoguided tumour localisation and therapy | |
| DE60320398T2 (en) | METHODS AND MEDICAL COMPOSITIONS FOR THE INTRAVESICAL TREATMENT OF BUBBLE CANCER | |
| Wilbanks et al. | Localization of mammary tumors in vivo with 131i‐labeled fab fragments of antibodies against mouse mammary epithelial (mme) antigens | |
| Kalofonos et al. | Antibody guided targeting of non-small cell lung cancer using 111In-labeled HMFG1 F (ab′) 2 fragments | |
| Sharkey et al. | Enhanced clearance of radiolabeled murine monoclonal antibody by a syngeneic anti‐idiotype antibody in tumor‐bearing nude mice | |
| Goldenberg | Imaging and therapy of gastrointestinal cancers with radiolabeled antibodies. | |
| Byers et al. | Biodistribution of ricin toxin A chain-monoclonal antibody 791T/36 immunotoxin and influence of hepatic blocking agents | |
| Gadina et al. | Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma MAb MOv18 | |
| Watanabe et al. | Effect of tumor mass and antigenic nature on the biodistribution of labeled monoclonal antibodies in mice | |
| Reintgen et al. | Immunodiagnosis of tumors in vivo using radiolabeled monoclonal antibody A2B5 | |
| AU730388B2 (en) | Antibodies with reduced net positive charge | |
| Bourguet et al. | Immunoscintigraphy of human lung squamous cell carcinoma using an iodine-131 labelled monoclonal antibody (Po66) | |
| Gasparini et al. | Tumor imaging of colo‐rectal carcinoma with an anti‐CEA monoclonal antibody | |
| Aarts et al. | Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti‐di‐diethylenetriaminepentaacetic acid F (ab′) 2 antibody | |
| JP2002509122A (en) | Use of radiolabeled monoclonal IgM in the treatment for cancer and autoimmune diseases | |
| Haisma et al. | Human IgM monoclonal antibody 16.88: pharmacokinetics and distribution in mouse and man. | |
| Harwood et al. | Human biodistribution of 111In-labeled B72. 3 monoclonal antibody |